US Patent 10457714 Acylated glucagon analogues
Patent 10457714 was granted and assigned to Zealand Pharma A/S on October, 2019 by the United States Patent and Trademark Office.
All edits
Edits on 9 Dec, 2023
Golden AI
Edits made to:
Article (+390 characters)
Article
Patent abstract
The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Edits on 3 Oct, 2023
Golden AI
Edits made to:
Infobox (+4 properties)
Infobox
Patent Inventor Names
Dieter Wolfgang Hamprecht0
Ditte Riber0
Jakob Lind Tolborg0
Wolfgang Rist0
Edits on 7 Apr, 2023
Golden AI
Infobox
Patent Citations
Edits on 2 Apr, 2023
Golden AI
Infobox
Patent Citations
Edits on 28 Sep, 2022
Golden AI
Infobox
Patent Citations
Edits on 22 Sep, 2022
Golden AI
Infobox
Patent Citations
Edits on 29 Jan, 2022
Golden AI
Edits made to:
Infobox (+12 properties)
US Patent 10457714 Acylated glucagon analogues
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10457714
Date of patent
October 29, 2019
Patent application number
15852458
Date Filed
December 22, 2017
Patent citations
Patent primary examiner
Find more entities like US Patent 10457714 Acylated glucagon analogues
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
